North American Biologicals, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Announces a public offering of 4.2 mil. shares of common stock. The Miami, Florida-based provider of human blood plasma elements and plasma/sera-based diagnostic products will offer 2.7 mil. shares, and two selling shareholders will offer 1.5 mil. Assuming the company's planned selling price of $6.50 per share, NABI will gain net proceeds of approximately $15.5 mil. through its 2.7 mil. shares. Additional proceeds could be realized through the sale of 630,000 over-allotment shares by underwriters Raymond James-& Associates and NatWest Securities Limited.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.